AstraZeneca has announced the withdrawal of its widely distributed COVID-19 vaccine, Vaxzevria, citing a surplus of newer vaccines targeting variants of the virus. This withdrawal marks the conclusion of a chapter in the pandemic response that saw the distribution of over 3 billion doses worldwide.
Also Read: New COVID-19 Variants FLiRT Spreads Fast in the US
AstraZeneca’s decision to withdraw its COVID-19 vaccine is from a decline in demand attributed to the availability of newer vaccines tailored to combatting variants of the virus.
The company stated that it would no longer manufacture or supply Vaxzevria, initiating the withdrawal of marketing authorizations within Europe and coordinating with regulators globally to go on the discontinuation of the vaccine where future commercial demand is not expected.
Independent estimates suggest that over 6.5 million lives were saved in the first year of its use alone. Governments worldwide have recognized its contributions considering it a critical component in the effort to curb the spread of COVID-19.
Vaxzevria, developed in partnership with the University of Oxford demonstrated overall safety in combating COVID-19.
It carried a rare but serious side-effect known as thrombosis with thrombocytopenia syndrome (TTS) occurring in approximately two to three individuals per 100,000 vaccinated.
This safety concern alongside the emergence of newer, more adaptable vaccines contributed to the decline in demand for Vaxzevria.
The advent of mRNA vaccines from Pfizer and Moderna heralded for their higher adaptability to emerging variants has reshaped vaccination strategies worldwide.
These mRNA vaccines utilize genetic material to instruct cells in producing the spike protein of the coronavirus.
AstraZeneca’s decision to withdraw Vaxzevria also carries commercial implications as the vaccine has not generated revenue for the company since April 2023.
The company faces legal challenges including a group action lawsuit in the UK alleging injuries caused by the vaccine.
AstraZeneca maintains that evidence from clinical trials and real-world data consistently supports the vaccine’s safety profile.
Also Read: UK Trials World’s First Personalized mRNA Vaccine for Melanoma
Initially lauded as a vaccine for the world due to its affordability and ease of storage, the vaccine encountered challenges including concerns over rare blood clotting events and production delays.
The withdrawal of the AstraZeneca vaccine extends to the European Union where the European Medicines Agency issued a notice confirming that Vaxzevria is no longer authorized for use within member states.
The withdrawal of the AstraZeneca vaccine reverberates globally affecting countries where the vaccine had been a cornerstone of COVID-19 vaccination campaigns.
The United Kingdom where the first dose of Vaxzevria was administered in January 2021 has ceased its use of the vaccine.
With over 3 billion doses supplied worldwide since its inception, Vaxzevria is credited with saving millions of lives particularly during the early stages of the pandemic when vaccine availability was limited.
As new variants of the virus continue to emerge there is a growing emphasis on the development of updated vaccines that can target these variants.
While the AstraZeneca vaccine demonstrated overall safety and efficacy, it was not without risks. The rare but serious side effect of thrombosis with thrombocytopenia syndrome (TTS) raised concerns contributing to hesitancy among some populations.
As vaccination efforts progress and populations become increasingly protected against COVID-19, the risk calculus surrounding vaccine deployment has evolved.
With a greater focus on targeting emerging variants and optimizing vaccine efficacy, newer vaccines have taken precedence over earlier iterations like Vaxzevria.
The emergence of mRNA vaccines such as those produced by Pfizer and Moderna has introduced new possibilities for combating COVID-19 and adapting to viral variants.
AstraZeneca faces legal challenges related to its vaccine including a group action lawsuit in the UK alleging injuries caused by Vaxzevria.
Also Read: HIV Linked to Vampire Facials at New Mexico Spa
